FDA outlines progress tackling opioid crisis

25 October 2019
addiction_pills_syringe_big

The US medicines regulator has provided an update on its work to address the country’s ongoing opioid epidemic, leveraging new  powers granted in 2018 under the SUPPORT Act.

As well as acting to prevent the importation of illegal opioids, the agency has used the powers to advance innovation in pain medicines with fewer risks than opioids, and develop better treatments for those with opioid use disorder (OUD).

The Food and Drug Administration said that, according to provisional data, total drug overdose deaths dropped 5.1% from 2017 to 2018.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical